m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG04272)
Name
VP-102
Status
Phase 3
TTD Drug ID
D01HZQ
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Protein phosphatase 1A (PPM1A)
Methyltransferase-like 14 (METTL14)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Protein phosphatase 1A (PPM1A) is a therapeutic target for VP-102. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of VP-102 through regulating the expression of Protein phosphatase 1A (PPM1A). [1], [2]
RNA demethylase ALKBH5 (ALKBH5)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Protein phosphatase 1A (PPM1A) is a therapeutic target for VP-102. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of VP-102 through regulating the expression of Protein phosphatase 1A (PPM1A). [1], [2]
YTH domain-containing family protein 1 (YTHDF1)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Protein phosphatase 1A (PPM1A) is a therapeutic target for VP-102. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of VP-102 through regulating the expression of Protein phosphatase 1A (PPM1A). [1], [2]
References
Ref 1 m(6)A mRNA methylation regulates testosterone synthesis through modulating autophagy in Leydig cells. Autophagy. 2021 Feb;17(2):457-475. doi: 10.1080/15548627.2020.1720431. Epub 2020 Jan 31.
Ref 2 The selective hypoxia inducible factor-1 inhibitor PX-478 provides in vivo radiosensitization through tumor stromal effects. Mol Cancer Ther. 2009 Apr;8(4):947-58. doi: 10.1158/1535-7163.MCT-08-0981.